LEXEO Therapeutics
New York
About LEXEO Therapeutics
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single gene mutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $514.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:LXEO
- Website: lexeotx.com
- Phone: (212) 547-9879
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lexeo-therapeutics-118811 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.